Welcome to Investor Relations

Abbisko Cayman Limited is a R&D-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since our inception, we have established a robust in-house R&D engine underpinned by our outstanding discovery team and multi-dimensional discovery platform. Leveraging strong discovery capabilities, we have strategically designed and developed a rich pipeline of 14 programs focused on oncology, including five assets at clinical stage.

Abbisko Therapeutics completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112
23 Feb. 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced the first patient dose has been completed with next-generation EGFR Exon20ins inhibitor ABSK112 for non-small cells lung cancer (NSCLC).
​US$70 million Arrived! Abbisko Therapeutics Announced it Received Upfront Payment Pursuant to the Licensing Agreement for Pimicotinib (ABSK021) with Merck
​On 6 Feb. 2024, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”) announced that it had received the upfront payment of US$70 million upon the entry into a licensing agreement for pimicotinib(ABSK021)with Merck in December 2023, a leading science and technology company headquartered in Darmstadt, Germany. It marks the successful completion of the first step in this collaboration. The receipt of this upfront payment will further bolster Abbisko Therapeutics's cash reserves and facilitate its subsequent pipeline R&D and internationalization strategy.
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib (ABSK021)
On January 9, 2024, Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib(ABSK021) has been granted orphan drug designation(ODD) by the European Medicines Agency (EMA) for the treatment of inoperable tenosynovial giant cell tumor (TGCT). 
Abbisko Therapeutic Completed the First Patient Dose in Phase I Clinical Trial for Novel Small Molecule CD73 Inhibitor ABSK051
3 January 2024, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that ABSK051, a novel small molecule CD73 inhibitor, has completed the first patient dose. In November 2023, Abbisko Therapeutics obtained the clinical trial approval from the National Medical Products Administration (NMPA) of the People’s Republic of China. ABSK051 is about to enter the first-in-human (FIH) phase I clinical trial for the treatment of advanced solid tumors in China.
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib(ABSK021)
​14 December 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) today announced that its CSF-1R inhibitor pimicotinib(ABSK021)has been granted the fast track designation(FTD) by the U.S. FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients that are not amenable to surgery.
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.
  • {{item.calendar_date.substr(8,2)}}
    {{item.meeting_time}} {{item.address}} {{item.address}}

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号